PepGen gets FDA clinical hold on CONNECT2 U.S. trial; Health Canada restricts dose escalation in CONNECT1

PepGen Inc.

10 mg/kg cohort fully enrolled (n=4); data expected year-end 2025.
One participant had eGFR reduction; dosing paused, eGFR improving.
Health Canada allows continued dosing at current levels but requests additional info before escalation.
FDA placed clinical hold on U.S. CONNECT2 trial; company working to address agency questions.
All treatment-related adverse events mild per Jan 23, 2025 update by CMO Paul Streck.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.